Siewert Type I Adenocarcinoma of Esophagogastric Junction
3
1
1
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Vactosertib
Related Conditions
Often studied with 8 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma
Morbidity and Mortality After Esophageal and Esophagogastric Junction Cancer Surgery
Classification of Adenocarcinoma of the Esophagogastric Junction
Research Network
Common Treatments
- Vactosertib1
- Elective Surgery For Gastric Cancer1
- Standard Of Care Preoperative Therapy1
Active Sponsors
- National Medical Research Radiological Centre of the Ministry of Health of Russia1
- Melissa Lumish1
- P. Herzen Moscow Oncology Research Institute1
- St. James's Hospital, Ireland1
Top Investigators
P.Herzen Moscow Oncological Research Institute
P.Herzen Moscow Oncological Research Institute
P.Herzen Moscow Oncological Research Institute
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
P.Herzen Moscow Oncological Research Institute
Related Conditions
- Siewert Type Ii Adenocarcinoma Of Esophagogastric Junction2
- Siewert Type Iii Adenocarcinoma Of Esophagogastric Junction2
- Adenocarcinoma Esophagus1
- Barrett Esophagus1
- Oesophagus Cancer1